(Q54028703)

English

Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients.

scientific article published in December 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients. (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Bensmaïne

1

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

de Gramont A

2

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

Brienza S

3

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

Marty M

4

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

Lévi F

5

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

Ducreux M

6

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

François E

7

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

Gamelin E

8

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

Bleiberg H

9

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

Bleuzen P

10

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

Simon J

11

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

Cvitkovic E

12

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

publication date

1 December 2000

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

36

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

18

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

2335-2343

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

Cancer statistics, 1992

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

High dose 5-fluorouracil (5-FU) and folinic acid in advanced colorectal cancer resistant to standard dose 5-FU treatment: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of chemotherapy of metastatic colorectal carcinoma with 5-fluorouracil plus cisplatin. A Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose continuous infusion 5-fluorouracil and cisplatin: phase II evaluation in advanced colorectal carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin: a review of preclinical and clinical studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuous-infusion 5-fluorouracil in metastatic colorectal cancer patients pretreated with bolus 5-fluorouracil: clinical evidence of incomplete cross-resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900305-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(00)00305-1

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/11094307

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54028703&oldid=1909615694"